The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The incretin hormone, glucagon‐like peptide 1 (GLP‐1), regulates gastric emptying, glucose‐dependent stimulation of insulin secretion and glucagon release, and GLP‐1 analogs are therefore approved for treatment of type II diabetes. GLP‐1 receptors are expressed in reward‐related areas such as the ventral tegmental area and nucleus accumbens, and GLP‐1 was recently shown to regulate several alcohol‐mediated behaviors as well as amphetamine‐induced, cocaine‐induced and nicotine‐induced reward. The present series of experiments were undertaken to investigate the effect of the GLP‐1 receptor agonist, liraglutide, on several alcohol‐related behaviors in rats that model different aspects of alcohol use disorder in humans. Acute liraglutide treatment suppressed the well‐documented effects of alcohol on the mesolimbic dopamine system, namely alcohol‐induced accumbal dopamine release and conditioned place preference in mice. In addition, acute administration of liraglutide prevented the alcohol deprivation effect and reduced alcohol intake in outbred rats, while repeated treatment of liraglutide decreased alcohol intake in outbred rats as well as reduced operant self‐administration of alcohol in selectively bred Sardinian alcohol‐preferring rats. Collectively, these data suggest that GLP‐1 receptor agonists could be tested for treatment of alcohol dependence in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 1×
“and extensively (Deacon et al. 1995), the clinically available GLP-1 receptor agonist, liraglutide, has protracted”
BackgroundAlhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · cited 1×
“able food as well as attenuated CPP for palatable food (Alhadeff et al. 2012; Dickson et al. 2012).”
BackgroundHunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
Linking context with reward: a functional circuit from hippocampal CA3 to ventral tegmental area
Luo, A. H., Tahsili-Fahadan, P., Wise, R. A., Lupica, C. R., & Aston-Jones, G. (2011) · Science · doi:10.1126/science.1204622 · Cited by 425
Dickson, S. L., Shirazi, R. H., Hansson, C., Bergquist, F., Nissbrandt, H., & Skibicka, K. P. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6326-11.2012 · Cited by 414 · cited 2×
“able food as well as attenuated CPP for palatable food (Alhadeff et al. 2012; Dickson et al. 2012).”
BackgroundFlint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384
Meeran, K., O’Shea, D., Edwards, C. M. B., Turton, M. D., Heath, M. M., Gunn, I., Abusnana, S., Rossi, M., Small, C. J., Goldstone, A. P., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6421 · Cited by 303
Cited by
The dopamine motive system: implications for drug and food addiction
Volkow, N. D., Wise, R. A., & Baler, R. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.130 · Cited by 939
Klausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A.-M. Ø., Zeeman, V. A., Johannsen, C.-F., Lee, A., Thomsen, G. K., Macoveanu, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159863 · Cited by 262
“Data from preclinical trials showed that high alcohol-consuming animals decreased their alcohol intake significantly more than low alcohol-consuming animals when treated with a GLP-1 receptor agonist (29,30).”
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259
“Systemically injected liraglutide (Vallöf et al., 2016) and exenatide (Egecioglu, Steensland, et al., 2013) attenuate alcohol-induced accumbal dopamine release, and exenatide injection into the NTS also attenuates this response as well (Vallöf, Vestlund, et al., 2019).”
BackgroundResultInfluentialSemaglutide reduces alcohol intake and relapse-like drinking in male and female rats
Aranäs, C., Edvardsson, C. E., Shevchouk, O. T., Zhang, Q., Witley, S., Blid Sköldheden, S., Zentveld, L., Vallöf, D., Tufvesson-Alm, M., & Jerlhag, E. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104642 · Cited by 158
Self-citationGLP-1a: Going beyond Traditional Use
Laurindo, L. F., Barbalho, S. M., Guiguer, E. L., da Silva Soares de Souza, M., de Souza, G. A., Fidalgo, T. M., Araújo, A. C., de Souza Gonzaga, H. F., de Bortoli Teixeira, D., de Oliveira Silva Ullmann, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020739 · Cited by 102
“Nevertheless, few studies investigated the patterns in different types of addiction; most have demonstrated the action only in cocaine and alcohol abuse [94,95].”
BackgroundEffects of dulaglutide on alcohol consumption during smoking cessation
Probst, L., Monnerat, S., Vogt, D. R., Lengsfeld, S., Burkard, T., Meienberg, A., Bathelt, C., Christ-Crain, M., & Winzeler, B. (2023) · JCI Insight · doi:10.1172/jci.insight.170419 · Cited by 94
“These results were largely reproduced using liraglutide (8), dulaglutide (9), and semaglutide (10).”
BackgroundJerlhag, E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1063033 · Cited by 80
“Similar to the results obtained with acute injection, repeated liraglutide treatment (six injections over 2 weeks) of alcoholexperienced male rats has been shown to decrease both alcohol consumption and preference for alcohol (Vallof et al., 2015).”
BackgroundResultSelf-citationBornebusch, A. B., Fink-Jensen, A., Wörtwein, G., Seeley, R. J., & Thomsen, M. (2019) · eneuro · doi:10.1523/eneuro.0443-18.2019 · Cited by 72
GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence
Jerlhag, E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.013 · Cited by 72
Self-citationDouton, J. E., Horvath, N., Mills‐Huffnagle, S., Nyland, J. E., Hajnal, A., & Grigson, P. S. (2022) · Addiction Biology · doi:10.1111/adb.13117 · Cited by 54
“observed to reduce alcohol-related behaviours in both rats and mice.(23) Given its longer half-life, LIR is administered only once per day in humans.”
BackgroundMethodInfluentialAlcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1
Jerlhag, E. (2020) · Brain Research · doi:10.1016/j.brainres.2019.146562 · Cited by 53
“In rats consuming alcohol for ten weeks in the intermittent access model, acute administration of liraglutide profoundly reduces alcohol intake and prevents relapse drinking (Vallof et al., 2015).”
InfluentialSelf-citationThe emerging role of glucagon-like peptide 1 in binge eating
Balantekin, K. N., Kretz, M. J., & Mietlicki-Baase, E. G. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0405 · Cited by 38
Farokhnia, M., Fede, S. J., Grodin, E. N., Browning, B. D., Crozier, M. E., Schwandt, M. L., Hodgkinson, C. A., Momenan, R., & Leggio, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-17190-3 · Cited by 32
Aranäs, C., Blid Sköldheden, S., & Jerlhag, E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1180512 · Cited by 20
“They are in further accordance with studies on other GLP-1R agonists, where their systemic administration lowers alcohol intake (Sanchis-Segura and Spanagel, 2006; Davis et al., 2012; Egecioglu et al., 2013; Shirazi et al., 2013; Suchankova et al., 2015; Vallof et al., 2015; Thomsen et al., 2017; Thomsen et al., 2019;…”
ResultSelf-citation
Metadata
- Authors
- Vallöf, D., Maccioni, P., Colombo, G., Mandrapa, M., Jörnulf, J. W., Egecioglu, E., Engel, J. A., & Jerlhag, E.
- Venue
- Addiction Biology
- Publisher
- Wiley
- Published
- 2015-08-25
- Volume
- 21
- Issue
- 2
- Pages
- 422-437
- ISSN
- 1355-6215 (ISSN-L)
- 1369-1600
- OpenAlex
- W1932004110
- Cited by
- 150
- References
- 15
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.